Studies

  1. Golimumab, Guselkumab or both in UC

  2. Neuroimmune modulation through vagus nerve stimulation in CD

  3. Vedolizumab in children with IBD

  4. Ritlecitinib and Brepocitinib in moderate-severe UC

  5. Upadacitinib maintenance in moderate-severe UC

  6. Upadacitinib in Crohn’s disease induction and maintenance

  7. Allopurinol-thiopurine versus standard thiopurine in patients with IBD

  8. Tofacitinib in acute severe ulcerative colitis

  9. Diverting ileostomy closure after pouch construction

  10. Infliximab or azathioprine withdrawal in CD